/ Home / Product Center / Advance Intermediates / Anti-Cancer /

Cabozantinib Intermediate

N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide L-malate
CAS
1140909-48-3
MF
C32H30FN3O10
MW
635.6
Purity
98%
Indication
Cabozantinib Intermediate
Description

Cabozantinib S-MALATE,formerly known as XL184, trade name Cabometyx, is developed by Exelixis biopharmaceutical company in the United States.